SCHEDULE: FMR LLC Boosts VAXCYTE Stake to 9.4%

FMR LLC and Abigail P. Johnson have disclosed a beneficial ownership of 9.4% in VAXCYTE INC common stock as of June 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively beneficially own 12,104,049.51 shares of VAXCYTE INC common stock.
• This aggregate ownership represents 9.4% of the total outstanding common stock of VAXCYTE INC.
• FMR LLC holds sole voting power over 12,052,875.00 shares and sole dispositive power over 12,104,049.51 shares.
• Abigail P. Johnson, as Director, Chairman, and CEO of FMR LLC, is also reported as a beneficial owner of the same aggregate amount of shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of VAXCYTE INC.
• Several FMR LLC subsidiaries, including Fidelity Management & Research Company LLC, are identified as entities that beneficially own shares, with Fidelity Management & Research Company LLC owning 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: The disclosure of a significant beneficial ownership stake by a prominent institutional investor like FMR LLC is generally viewed positively, indicating confidence in the company. However, as a Schedule 13G, it provides no operational or financial performance details of the issuer.

Positives

• A significant stake by a major institutional investor like FMR LLC indicates confidence in VAXCYTE INC's prospects.
• The acquisition of shares in the ordinary course of business suggests a long-term investment strategy rather than a short-term speculative move.

Risks

• Members of the Johnson family, including Abigail P. Johnson, may be deemed to form a controlling group with respect to FMR LLC under the Investment Company Act of 1940 due to their ownership of Series B voting common shares and a shareholders' voting agreement.

Future Outlook

The filing does not provide forward-looking statements or guidance regarding VAXCYTE INC's future performance or strategic direction, focusing solely on beneficial ownership disclosure.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

This filing is a standard disclosure for large institutional investors acquiring significant stakes in publicly traded companies. It reflects FMR LLC's investment strategy within the broader market, potentially signaling its view on the biotechnology or pharmaceutical sector where VAXCYTE INC operates.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor's stake may instill confidence and potentially influence market perception and share price.
• Investment Professionals: Provides transparency into major institutional holdings, aiding in market analysis and investment decision-making.

Key Dates

Keywords

VAXCYTE INC, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Schedule 13G, Biotechnology, Pharmaceuticals